Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C9H19N.C4H6O6 |
| Molecular Weight | 291.3407 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(C)CCC=C(C)C.O[C@H]([C@@H](O)C(O)=O)C(O)=O
InChI
InChIKey=HLRDXBKIKFQOFS-LREBCSMRSA-N
InChI=1S/C9H19N.C4H6O6/c1-8(2)6-5-7-9(3)10-4;5-1(3(7)8)2(6)4(9)10/h6,9-10H,5,7H2,1-4H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02290379 | https://www.ncbi.nlm.nih.gov/pubmed/22288671 | https://clinicaltrials.gov/ct2/show/NCT02706015 | https://www.drugbank.ca/drugs/DB06706
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02290379 | https://www.ncbi.nlm.nih.gov/pubmed/22288671 | https://clinicaltrials.gov/ct2/show/NCT02706015 | https://www.drugbank.ca/drugs/DB06706
Isometheptene (usually as isometheptene mucate) is a sympathomimetic amine sometimes used in the treatment of migraines and tension headaches due to its vasoconstricting properties. Isometheptene's vasoconstricting properties arise through activation of the sympathetic nervous system via epinephrine and norepinephrine. These compounds elicit smooth muscle activation leading to vasoconstriction by interacting with cell surface adrenergic receptors.
Originator
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
120 mg 1 times / episode multiple, oral Studied dose Dose: 120 mg, 1 times / episode Route: oral Route: multiple Dose: 120 mg, 1 times / episode Co-administed with:: dipyrone(1200 mg) Sources: caffeine(120 mg) |
unhealthy, 18 to 65 years n = 76 Health Status: unhealthy Condition: primary headache Age Group: 18 to 65 years Sex: M+F Population Size: 76 Sources: |
Other AEs: Angioneurotic edema, Epigastralgia... Other AEs: Angioneurotic edema (grade 1, 1.3%) Sources: Epigastralgia (grade 1, 1.3%) |
780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years n = 36 Health Status: unhealthy Condition: migraine Age Group: mean age 33 years Sex: M+F Population Size: 36 Sources: |
Other AEs: Dizziness, Numbness... Other AEs: Dizziness (17.1%) Sources: Numbness (5.7%) Shortness of breath (2.8%) Chills (2.8%) Nausea (2.8%) Drowsiness (2.8%) |
65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
Other AEs: Abdominal pain, Nausea... Other AEs: Abdominal pain (3.1%) Sources: Nausea (3.1%) Lightheadedness (6.1%) Sleepiness (3.1%) Dry mouth (1.5%) Hot flashes (1.5%) Palpitations (1.5%) Enlarged thyroid (1.5%) Confusion (1.5%) |
325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
Other AEs: Nausea, Vertigo... Other AEs: Nausea (40%) Sources: Vertigo (8%) Lump feeling in throat (8%) Drowsiness (4%) Tachycardia (4%) Itching (4%) Dry mouth (4%) Weakness of limbs (4%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Angioneurotic edema | grade 1, 1.3% | 120 mg 1 times / episode multiple, oral Studied dose Dose: 120 mg, 1 times / episode Route: oral Route: multiple Dose: 120 mg, 1 times / episode Co-administed with:: dipyrone(1200 mg) Sources: caffeine(120 mg) |
unhealthy, 18 to 65 years n = 76 Health Status: unhealthy Condition: primary headache Age Group: 18 to 65 years Sex: M+F Population Size: 76 Sources: |
| Epigastralgia | grade 1, 1.3% | 120 mg 1 times / episode multiple, oral Studied dose Dose: 120 mg, 1 times / episode Route: oral Route: multiple Dose: 120 mg, 1 times / episode Co-administed with:: dipyrone(1200 mg) Sources: caffeine(120 mg) |
unhealthy, 18 to 65 years n = 76 Health Status: unhealthy Condition: primary headache Age Group: 18 to 65 years Sex: M+F Population Size: 76 Sources: |
| Dizziness | 17.1% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years n = 36 Health Status: unhealthy Condition: migraine Age Group: mean age 33 years Sex: M+F Population Size: 36 Sources: |
| Chills | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years n = 36 Health Status: unhealthy Condition: migraine Age Group: mean age 33 years Sex: M+F Population Size: 36 Sources: |
| Drowsiness | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years n = 36 Health Status: unhealthy Condition: migraine Age Group: mean age 33 years Sex: M+F Population Size: 36 Sources: |
| Nausea | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years n = 36 Health Status: unhealthy Condition: migraine Age Group: mean age 33 years Sex: M+F Population Size: 36 Sources: |
| Shortness of breath | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years n = 36 Health Status: unhealthy Condition: migraine Age Group: mean age 33 years Sex: M+F Population Size: 36 Sources: |
| Numbness | 5.7% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years n = 36 Health Status: unhealthy Condition: migraine Age Group: mean age 33 years Sex: M+F Population Size: 36 Sources: |
| Confusion | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Dry mouth | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Enlarged thyroid | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Hot flashes | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Palpitations | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Abdominal pain | 3.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Nausea | 3.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Sleepiness | 3.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Lightheadedness | 6.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Co-administed with:: dichloralphenazone(500 mg per 12 h) Sources: acetaminophen(1625 mg per 12 h) |
unhealthy, mean age 40.9 years n = 65 Health Status: unhealthy Condition: migraine Age Group: mean age 40.9 years Sex: M+F Population Size: 65 Sources: |
| Drowsiness | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
| Dry mouth | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
| Itching | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
| Tachycardia | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
| Weakness of limbs | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
| Nausea | 40% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
| Lump feeling in throat | 8% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
| Vertigo | 8% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Co-administed with:: acetaminophen(325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months) Sources: |
unhealthy, mean age 49 years n = 25 Health Status: unhealthy Condition: migraine Age Group: mean age 49 years Sex: M+F Population Size: 25 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetised dogs. | 2001 Jul |
|
| Fixed drug combinations for the acute treatment of migraine : place in therapy. | 2005 |
|
| Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. | 2006 Dec |
|
| Intracerebral hemorrhage in postpartum cerebral angiopathy associated with the use of isometheptene. | 2006 Nov |
|
| Acute migraine: Current treatment and emerging therapies. | 2007 Jun |
|
| Current and prospective pharmacological targets in relation to antimigraine action. | 2008 Oct |
|
| Rizatriptan for the acute treatment of migraine: Consistency, preference, satisfaction, and quality of life. | 2009 Nov 3 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29709
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
227-795-9
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
PRIMARY | |||
|
5984-50-9
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
PRIMARY | |||
|
22296
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
PRIMARY | |||
|
DTXSID50975239
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
PRIMARY | |||
|
C4625WF7BM
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
PRIMARY | |||
|
C87580
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
PRIMARY | |||
|
m6501
Created by
admin on Fri Dec 15 16:01:15 GMT 2023 , Edited by admin on Fri Dec 15 16:01:15 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD
